Who
Neal Franklin Fowler
Director
Company insider
Files Form 4 as: Director, Emergent BioSolutions; Chief Executive Officer, Liquidia; Chief Executive Officer, Liquidia Technologies; Director, Aralez Pharmaceuticals; Director, Pozen Inc /nc.
In numbers
- Trades disclosed
- 44
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $204K
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 10 Jun 2010
- Last trade
- 30 Apr 2026
- Last filed
- 4 May 2026
Companies traded
Activity over time
1 Mar 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,296 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —25,344 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,824 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —34,403 at $0.00 | filing |
| 12 Mar 2025filed 12 Mar 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $204K35,000 at $5.83 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,748 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —17,430 at $0.00 | filing |
| 3 Oct 2023filed 5 Oct 2023 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —118,670 at $0.00 | filing |
| 19 Nov 2020filed 20 Nov 2020 | LQDA Liquidiaoption or derivative · Biotechnology | SEC FORM 4 Code M | —62,885 at $0.00 | filing |
| 19 Nov 2020filed 20 Nov 2020 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code M | $116K62,885 at $1.85 | filing |
| 19 Nov 2020filed 20 Nov 2020 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code F | $121K35,684 at $3.40 | filing |
| 18 Mar 2020filed 20 Mar 2020 | Liquidia Technologiesoption or derivative | SEC FORM 4 Code A | —121,600 at $0.00 | filing |
| 18 Mar 2020filed 20 Mar 2020 | Liquidia Technologies | SEC FORM 4 Code A | —30,400 at $0.00 | filing |
| 5 Feb 2019filed 7 Feb 2019 | Liquidia Technologiesoption or derivative | SEC FORM 4 Code A | —96,500 at $0.00 | filing |
| 12 Oct 2018filed 16 Oct 2018 | Liquidia Technologies | SEC FORM 4 Code A | —11,238 at $0.00 | filing |
| 25 Jul 2018filed 27 Jul 2018 | Liquidia Technologiesoption or derivative | SEC FORM 4 Code A | —192,008 at $0.00 | filing |
| 11 May 2017filed 12 May 2017 | Aralez Pharmaceuticals | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 11 May 2017filed 12 May 2017 | Aralez Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026
0 headlines in the last 90 days name Neal Franklin Fowler; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.